BioCryst (BCRX) announced that the Health Services Executive, or HSE, in Ireland has recommended Orladeyo for the routine prevention of recurrent attacks of hereditary angioedema, or HAE, in eligible patients
BioCryst (BCRX) announced that the Health Services Executive, or HSE, in Ireland has recommended Orladeyo for the routine prevention of recurrent attacks of hereditary angioedema, or HAE, in eligible patients
משמעות הדבר היא שחולי HAE באירלנד יכולים כעת לגשת לטיפול הראשון לבליעה, פעם ביום, להפחתת התקפות חוזרות אלו. ההחלטה של HSE באירלנד מגיעה לאחר שהנציבות האירופית אישרה את שיווק Orladeyo
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on BioCryst (BCRX – Research Report) today. The company’s shares opened today at $7.62. Ahmad covers the Healthcare sector,
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Verona Pharma (VRNA), 261% surge in interest Viking Therapeutics
Evercore ISI analyst Liisa Bayko maintained a Buy rating on BioCryst (BCRX – Research Report) today and set a price target of $10.00. The company’s shares closed yesterday at $7.35.